Paid Clinical Trials Quebec City
Discover 362 paid clinical trials in Quebec City, Quebec. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass SurgeryEffect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery
Sponsor:
Unity Health Toronto
Location:
Code:
NCT03900026
Conditions
Coronary Artery Bypass Graft Surgery
Atherosclerosis
Vein Occlusion
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Evolocumab
Placebo
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's DiseaseReal-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
Sponsor:
AbbVie
Location:
Code:
NCT06107426
Conditions
Parkinson's Disease (PD)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.
Sponsor:
CHU de Quebec-Universite Laval
Location:
Code:
NCT04655365
Conditions
Prostate Cancer
Eligibility Criteria
Sex: Male
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Enzalutamide capsule
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Sponsor:
Hoffmann-La Roche
Location:
Code:
NCT06065748
Conditions
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Giredestrant
Fulvestrant
Abemaciclib
Palbociclib
Ribociclib
Angiomammography and Neoadjuvant ChemotherapyAngiomammography and Neoadjuvant Chemotherapy
Sponsor:
CHU de Quebec-Universite Laval
Location:
Code:
NCT05402930
Conditions
Breast Neoplasms
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Angiomammography
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
Sponsor:
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Location:
Code:
NCT04945460
Conditions
Hypertension, Pulmonary
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Sotatercept 0.3 mg/kg
Placebo
Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary FibrosisA Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Sponsor:
Bristol-Myers Squibb
Location:
Code:
NCT06003426
Conditions
Idiopathic Pulmonary Fibrosis
Eligibility Criteria
Sex: All
Age: 40+
Healthy Volunteers: Not accepted
Interventions
BMS-986278
BMS-986278 Placebo
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology ProductsA Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
Sponsor:
Hoffmann-La Roche
Location:
Code:
NCT05476926
Conditions
Neovascular Age-related Macular Degeneration
Diabetic Macular Edema
Retinal Vein Occlusion
Branch Retinal Vein Occlusion
Central Retinal Vein Occlusion
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Faricimab
Port Delivery System with Ranibizumab
A Phase 1/2 Study of [225Ac]-FPI-1434 InjectionA Phase 1/2 Study of [225Ac]-FPI-1434 Injection
Sponsor:
Fusion Pharmaceuticals Inc.
Location:
Code:
NCT03746431
Conditions
Advanced Solid Tumours
Endometrial Cancer
Cervical Cancer
Ovarian Cancer
Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
[111In]-FPI-1547 Injection
[225Ac]-FPI-1434 Injection multi-dose
FPI-1175 Infusion
[225Ac]-FPI-1434 Injection single-dose